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Abstract
Uveitis treatment involves topical corticosteroids along with cycloplegic-mydriatics. Particularly severe cases may
require systemic corticosteroids and immunosuppressive drugs. Vernal keratoconjunctivitis (VKC) treatment consists
of a brief period of topical corticosteroids and/or cyclosporine. In patients refractory to traditional treatment, the
use of 0.1% topical ophtalmic FK- 506 (tacrolimus) ointment has been occasionally reported.
This is the first report of the coexistence of uveitis and VKC. The documented response to topical tacrolimus
eyedrop of uveitis and VKC is also of interest, in particular since to our knowledge there are no published reports
on its clinical use in uveitis.
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Background
Uveitis is an inflammation of the uveal tract or of the
adjacent ocular structures. Commonly uveitis is idio-
pathic, but identifiable causes have been reported as
well (e.g. infections; systemic diseases). These systemic
illnesses are usually driven by autoimmune mechanisms,
particularly in those children with connective tissue
involvement [1]. Juvenile idiopathic arthritis (JIA) is
commonly associated with chronic iridocyclitis in chil-
dren [2], particularly in those with oligoarticular onset
and antinuclear antibody (ANA) positivity. Unlike most
forms of anterior uveitis, the onset of chronic uveitis in
JIA patients tends to be insidious and entirely asympto-
matic, although later in the course of the disease, some
children may develop symptoms attributable to uveitis
(pain, redness, headache, photophobia, vision changes).
JIA-associated uveitis typically affects girls and is bilat-
eral. Recurrences are frequent and an active state of
inflammation may alternate between eyes [2]. Several
other autoimmune conditions may involve the uvea:
spondyloarthropathies, sarcoidosis, Behçet’ss y n d r o m e ,
Vogt- Koyanagi-Harada (VKH) syndrome, vasculitides
such as Wegener’s granulomatosis and Kawasaki disease
and inflammatory bowel diseases.
The active phase of inflammation usually requires
topical corticosteroids along with cycloplegic- mydria-
tics. Systemic corticosteroids and immunosuppressive
drugs have often been employed for the severe or
chronic patterns of the disease [3]. In the last 10 years,
anti-TNF drugs have been successfully utilized for the
treatment of uveitis and have become a useful tool for
clinicians [4]. Vernal keratoconjunctivitis (VKC) is a
chronic, bilateral inflammation of the superior tarsal
and limbar palpebral conjunctiva. The onset typically
occurs between 3 and 25 years of age. The most com-
mon symptoms are itching, photophobia, burning, and
lacrimation. The clinical signs consist of large conjuncti-
val papillae on the back of the superior tarsus, raised
Horner-Trantas dots (gelatinous, white clumps of
degenerated eosinophils usually located at the superior
limbus), areas of superficial punctate keratitis and, in
severe cases, well-demarcated, sterile corneal shield
ulcers, superiorly located [5].
VKC may be somehow linked to atopic conditions. In
fact, a positive response to skin and Radio-Allergo-Sor-
bent Test (RAST) was found in 57% and 52% of VKC
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levels have been shown to be elevated [6] and local pro-
duction of IgE in tears has also been postulated [7]. The
pathogenesis remains still unknown but a T helper (Th)
2- driven mechanism with mast cell, eosinophilic, lym-
phocytic involvement together with the production of
both regulatory and inflammatory cytokines such as IL-
4, IL-5, IL-13, has also been postulated [8]. The treat-
ment consists of topical corticosteroids that should be
carefully administered just for short periods, in order to
avoid a possible secondary development of glaucoma
and/or cataract [9]. A 1-2% solution of topical cyclos-
porine eyedrops can be considered as an alternative
[10]. In patients refractory to traditional treatments,
0.1% topical ophthalmic FK-506 (tacrolimus) eyedrops
have been tried [11]. Tacrolimus is a macrolide antibio-
tic with potent immunosuppressive activity. It belongs
to the calcineurin-inhibitor family and has immunosup-
pressive activity similar to cyclosporine.
Uveitis and VKC seem to arise from two different,
evenly opposed immunologic pathways: on one side Th1
cells, that are known to be involved in the pathogenesis
of organ-specific autoimmune disorders; on the other a
Th2 response which is responsible for atopic disorders
in genetically susceptible individuals. Both VKC and
uveitis can be considered rare diseases. The incidence of
VKC was reported to be 1/100,000/year, with a higher
rate in males under 16 years of age (10/100,000). It has
ap r e v a l e n c eo f7 . 8 / 1 0 0 , 0 0 0 ,a g a i nw i t hah i g h e rr a t ei n
young males (57/100,000) [12]. Uveitis incidence varies
between 17 and 27 new cases per 100,000 people per
year. In children uveitis rates are lower with a variable
annual incidence from 4.3 to 6.9 per 100,000 and a pre-
valence of 30 cases/100,000 [13].
We report here the unusual association between uvei-
tis and vernal keratoconjunctivitis in three children
referred to A. Meyer Children’sH o s p i t a li nF l o r e n c e ,
Italy, as well as the encouraging response of both uveitis
and VKC to 0.1% topical FK-506 (tacrolimus) eyedrops
application. Such a medication has been prepared by
Prograf. One ml = 5 mg vial of tacrolimus (Astellas
Pharma Spa) is diluted with 4 ml of Polyvinil alchol,
Hypotears (Novartis Pharma Spa).
Case Presentations
Case 1
After the diagnosis of ANA-positive polyarticular JIA, a
3-year-old female started to be treated with non-steroi-
dal anti-inflammatory drugs (NSAIDS, ibuprofen 10 mg/
kg/dose 3 times a day), methotrexate (15 mg/m
2/subcu-
t a n e o u s l yo n c eaw e e k )a n dl a t e rw i t he t a n e r c e p t( a n t i -
TNF soluble receptor antagonist; dosage: 0.8 mg/kg sub-
cutaneously once a week) with good clinical control of
arthritis. She was 5 years old, still on etanercept and
methotrexate, when uveitis was diagnosed. Her exam
showed the presence of keratic precipitates and a posi-
tive Tyndall sign (++) with cell grading of 3 on slit lamp
exam. Her etanercept was stopped. The patient was
started on topical steroids (dexamethasone: 2 drops per
eye three times a day) and mydriatic drops (1 drop per
eye once a day). The uveitis responded to drops and
methotrexate. Unfortunately the methotrexate had to be
stopped after 3 months due to liver enzyme elevation.
As a consequence, relapses did persist almost three
times a year, requiring repeated topical steroid courses.
Three years later during the spring, she started to com-
plain of itching and photophobia. The ophthalmologic
examination revealed clinical giant tarsal follicular con-
junctivitis with Horner-Trantas dots (Figure 1), leading
to the diagnosis of VKC. Topical 1% cyclosporine A was
started without improvement. During such a treatment
regimen, uveitis flares frequently occurred every three
months, requiring the employment of topical steroids to
obtain a good control of both VKC and uveitis. Because
of the persistence of VKC and the recurrences of uveitis,
0.1% topical ophthalmic FK-506 (tacrolimus) eyedrops
were started (1 drop per eye three time a day). VKC
relief was prompt, and interestingly, her uveitis also
resolved. Treatment with topical tacrolimus was contin-
ued for three months. then it was tapered and finally
stopped after six months from its introduction. During
the following 10 months of follow-up since it was com-
pletely withdrawn, no new uveitis flares occurred.
Case 2
A 3 year-old female was referred to our Rheumatology
Unit for an 8-week history of knee effusion. Physical
examination was unremarkable except for the presence
of left knee arthritis. Laboratory findings were all
Figure 1 Giant tarsal follicular conjunctivitis in a patient with
Vernal Keratoconjunctivitis (VKC).
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recent history, the clinical features and the presence of
asymptomatic uveitis (keratic precipitates and positive
Tyndall sign ++, and a cell grading of 3 in the left eye
were consistent with oligoarticular JIA with uveitis.
After an unsuccessful trial with NSAIDS (ibuprofen 10
mg/kg/dose 3 times a day), methotrexate was promptly
started (15 m
2/subcutaneously once a week) with excel-
lent improvement of the arthritis. Unfortunately, uveitis
rapidly affected both eyes and frequently flared (almost
every three months) requiring topical steroids (dexa-
methasone: 2 drops per eye three times a day) and
cyclopegic drugs (1 drop per eye once a day). One year
later, during a phase of uveitis quiescence, she started to
complain of photophobia and itching. Giant tarsal papil-
lar conjunctivitis and Horner-Trantas dots were found,
allowing the diagnosis of VKC which was successfully
treated with topical 1% cyclosporine A (1 drop per eye
twice a day). Unfortunately, because of burning on
application of the medication, the patient stopped the
cyclosporine two months later. The VKC then flared
again.
Due to the flare of the VKC and the uveitis, 0.1% topi-
cal ophthalmic FK-506 (1 drop per eye three time a day)
was started one month later. The VKC rapidly
improved, and surprisingly, the uveitis completely
resolved in a few days. Topical tacrolimus was contin-
ued at full dosage for the first three months and then
tapered and stopped within 5 months from its introduc-
tion. For the next 12 months, no flares of the VKC or
uveitis occurred.
Case 3
A 7 year-old female was referred to our Ophthalmologic
Unit because of a two year history of ocular burning
and lacrimation with photophobia, usually worse from
March to October. Clinical signs of VKC were found
(giant limbar papillar conjunctivitis and Horner-Trantas
dots). Slit lamp exam also detected keratic precipitates
and a positive Tyndall sign (cell grading: 2), consistant
with bilateral uveitis. No infections and/or systemic
associated diseases were detected and the diagnosis of
idiopathic uveitis was made. VKC was successfully con-
trolled with topical 1% cyclosporin A (1 drop per eye
twice a day), but frequent uveitis relapses required sev-
eral topical steroid courses (dexamethasone: 2 drops per
eye three times a day) and cyclopegic drugs (1 drop per
eye once a day). For this reason and on the basis of the
previous two cases, 0.1% topical treatment with FK-506
eyedrops was started (1 drop per eye three time a day),
with a prompt recovery of both the diseases within 10
days. Topical tacrolimus was maintained at full dosage
for three months before tapering and then discontinued
after six months. VKC and uveitis were still in remission
off therapy after a follow-up of one year. No sign or
symptom compatible with a rheumatic disease later
appeared.
Discussion
We have described three children with coexisting uveitis
a n dV K C ,w h or e s p o n d e dw e l lt ot o p i c a lt a c r o l i m u sf o r
both conditions. The treatment regimen used for the
three patients (two children had JIA-related uveitis, the
third child suffered from an idiopathic form) was the
same. At the time of starting tacrolimus eye drops, no
other topical drugs had been recently utilized and chil-
dren receiving systemic treatment for JIA continued
with the same regimen. No child was simultaneously
taking systemic or topical corticosteroids while on topi-
cal tacrolimus. The drug was prepared by Prograf
® and
was administered three times a day (one drop per eye).
The dilutions remained stable for a month if kept at 4°
C. All patients received the full dosage for the first three
months, then the tacrolimus was tapered until complete
cessation within six months of starting the tacrolimus.
Our current clinical practice for chronic uveitis man-
agement includes the use of topical corticosteroids
along with cycloplegic-mydriatics initially. Immunosup-
pressant drugs such as methotrexate and cyclosporine A
and eventually anti-TNF drugs are used for resistant
cases. There has been no data about the use of topical
tacrolimus in anterior uveitis. Yet since the morbidity of
c h r o n i cu v e i t i si sh i g ha n ds y s t e m i cd r u g sm a yc a u s e
severe side effects, topical tacrolimus might be a valid
alternative for mild-moderate recurrent uveitis flares.
Severe recurrent flares may need more aggressive regi-
men options.
To our knowledge, topical tacrolimus has been used
by intravitreal injection in animal models, but no reports
have been published on its use for human anterior uvei-
tis [14]. There have been reports on tacrolimus treat-
ment for immune posterior uveitis. Posterior uveitis
likely reflects different pathogenetic pathways and is
seen in other conditions, like Behcet’s disease or Crohn’s
disease [15,16]. In these reports systemic tacrolimus was
given with good efficacy on uveitis control and excellent
safety profile.
Further studies on larger cohorts of patients are
needed to evaluate the efficacy and the safety of topical
tacrolimus for the treatment of anterior uveitis. More-
over, the employment of topical tacrolimus may expose
the patient to a higher risk of herpes keratitis, but so far
this kind of complication has not been described. In the
three cases reported, only mild discomfort was asso-
ciated with its application (even at the concentration of
0.1% which is higher than the 0.03% described in the lit-
erature) such as a temporary sense of burning during
the very first days of therapy.
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adsorption when administered in the eyes of rabbits
even at a concentration 10 times higher than the one
we used [17]. According to our experience, no clinical
side effects were observed. Every three months liver and
renal functions were tested and always found normal,
and serum tacrolimus levels always remained within the
normal range.
In all 3 cases described, uveitis frequently recurred,
requiring several courses of topical steroids. In the two
cases with JIA-related uveitis, systemic treatment (meth-
otrexate alone or with anti-TNF antagonist receptor)
was useful for control of the arthritis but did not show
any relevant clinical effects on eye symptoms. It is
important to point out that JIA-associated uveitis is
known to have relapses and it is expected to have an
asymmetric course. A one year follow-up period might
not be considered sufficient. During this one year period
our patients underwent two monthly ophthalmologic
evaluations that did not reveal signs attributable to uvei-
tis. However, none of our patients had experienced such
a long uveitis-free period in the past, supporting the
clinical benefits of tacrolimus. In our first patient, uveitis
developed while on therapy with etanercept. There have
been reports of etanercept itself triggering uveitis [4].
However, etanercept was withdrawn with no significant
amelioration of the uveitis.
To our knowledge, this is the first report describing
the association between an allergic chronic ocular dis-
ease such as VKC with an autoimmune disease such as
uveitis.
Recent reports have shown that the Th1-proinflamma-
tory cytokine IFN-g, and the Th2, IL-4, IL-13 cytokines,
may coexist in both inflammatory and allergic responses
[12]. Other experimental studies have challenged the
Th1-Th2 balance paradigm in both allergic diseases and
in uveitis [18].
In our hospital, we follow 408 patients affected by
VKC and 99 children with uveitis. Considering that
three patients had both diseases, we can assume that the
prevalence of uveitis in VKC patients is much higher
(0.7%) than in controls (0.02%). Similarly, VKC seems to
be more frequently associated with uveitis, with a preva-
l e n c eo f3 % .T h e s ec o n s i d e r a t i o n sm a k ei tu n l i k e l yt h a t
the coexistence of the two diseases in the same patient
could be considered a mere coincidence, even if the
explanation of the relationship is still unknown.
Conclusion
We report 3 children who simultaneously developed
VKC and anterior uveitis, 2 who had JIA and one child
with idiopathic uveitis. All 3 children failed conventional
topical and systemic treatment for their eye disease
before the use of topical tacrolimus appeared to put
both eye diseases in remission for at least one year. The
use of topical tacrolimus for severe eye problems such
as resistant VKC and uveitis should be explored further.
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